VolitionRx Limited (VNRX)
| Market Cap | 49.11M |
| Revenue (ttm) | 1.29M |
| Net Income (ttm) | -29.87M |
| Shares Out | 92.66M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 389,200 |
| Open | 0.5600 |
| Previous Close | 0.5100 |
| Day's Range | 0.5200 - 0.5700 |
| 52-Week Range | 0.4300 - 1.0200 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 4.17 (+686.79%) |
| Earnings Date | May 12, 2025 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer det... [Read more]
Financial Performance
In 2023, VolitionRx's revenue was $775,302, an increase of 153.04% compared to the previous year's $306,392. Losses were -$35.32 million, 16.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price forecast is $4.17, which is an increase of 686.79% from the latest price.
News
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on W...
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PR...
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev.
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev. , March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICA...
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 HENDERSON, Nev. , March 20,...
Volition Proudly Sponsors the 44th ISICEM Congress
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 HENDERSON, Nev. , March 17, 2025 /PRNewswire/ --...
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
HENDERSON, Nev. , March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test...
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
Published study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening. The study is expected to be completed by the end of 2025 HENDERSON, Nev.
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
Nu.Q® Discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development pathways from discovery to market ready HENDE...
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
Volition will showcase presentations from Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, Dr. Brett Cordes, DVM, and Dr. Tom Butera, DVM Representatives will also be available at exhibition booth #2943 HEND...
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies HENDERSON, Nev. , Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN...
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
HENDERSON, Nev. , Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Fri...
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
HENDERSON, Nev. , Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which sh...
Volition Issues Business Review 2024
HENDERSON, Nev. , Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outli...
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15 th, 2025 at the Beacon Grand Hotel in San Francisco. HENDERSON, Nev.
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
HENDERSON, Nev. , Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which sh...
VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev , Dec. 6, 2024 /PRNew...
VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript
VolitionRx Limited (NYSE:VNRX) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Tom Butera - CEO, Volitio...
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
Volition Appoints Timothy I. Still as Chairman
HENDERSON, Nev. , Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of dire...
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
HENDERSON, Nev. , Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report , from its 'NETs in sepsis managemen...
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
HENDERSON, Nev. , Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expou...
Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
HENDERSON, Nev. , Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on O...
Volition Appoints Dr. Ethel Rubin as an Independent Director
HENDERSON, Nev. , Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, a...